TY - JOUR
T1 - Characterization and Management of Stable Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation
AU - Sammartino, Sofia
AU - Laterra, Giulia
AU - Pilgrim, Thomas
AU - Amat Santos, Ignacio J
AU - De Backer, Ole
AU - Kim, Won-Keun
AU - Ribeiro, Henrique Barbosa
AU - Saia, Francesco
AU - Bunc, Matjaz
AU - Tchetche, Didier
AU - Garot, Philippe
AU - Ribichini, Flavio Luciano
AU - Mylotte, Darren
AU - Burzotta, Francesco
AU - Watanabe, Yusuke
AU - Bedogni, Francesco
AU - Tesorio, Tullio
AU - Rheude, Tobias
AU - Sardella, Gennaro
AU - Tocci, Marco
AU - Franzone, Anna
AU - Valvo, Roberto
AU - Savontaus, Mikko
AU - Wienemann, Hendrik
AU - Porto, Italo
AU - Gandolfo, Caterina
AU - Iadanza, Alessandro
AU - Bortone, Alessandro Santo
AU - Mach, Markus
AU - Latib, Azeem
AU - Biasco, Luigi
AU - Taramasso, Maurizio
AU - De Marco, Federico
AU - Frittitta, Valentina
AU - Dipietro, Elena
AU - Reddavid, Claudia
AU - Strazzieri, Orazio
AU - Motta, Silvia
AU - Comis, Alessandro
AU - Melfa, Chiara
AU - Calì, Mariachiara
AU - Sgroi, Carmelo
AU - Abdel-Wahab, Mohamed
AU - Stefanini, Giulio
AU - Tamburino, Corrado
AU - Barbanti, Marco
AU - Costa, Giuliano
PY - 2024
Y1 - 2024
N2 - Background/Objectives: To date, data regarding the characteristics and management of obstructive, stable coronary artery disease (CAD) encountered in patients undergoing transcatheter aortic valve implantation (TAVI) are sparse. The aim of the study was to analyze granular details, treatment, and outcomes of patients undergoing TAVI with obstructive, stable CAD from real-world practice. Methods: REVASC-TAVI (Management of myocardial REVASCularization in patients undergoing Transcatheter Aortic Valve Implantation with coronary artery disease) is an investigator-initiated, multicenter registry, which collected data from patients undergoing TAVI with obstructive stable CAD found during the pre-TAVI work-up. Results: A total of 2025 patients from 30 centers worldwide with complete follow-up were included in the registry. Most patients had single-vessel CAD (56.1%). An involvement of proximal coronary tracts was detected in 62.5% of cases, with 12.0% of patients having CAD in left main (LM). Most patients received percutaneous coronary intervention (PCI) (n = 1617, 79.9%), especially those with proximal CAD (90.4%). At 2 years, the rates of all-cause death [Kaplan-Meier (KM) estimates 20.1% vs. 18.8%, plog-rank = 0.86] and of the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure (KM estimates 29.7% vs. 27.5%, plog-rank = 0.82) did not differ between patients undergoing PCI and those who were not. Conclusions: Patients undergoing TAVI with obstructive CAD more commonly had a single-vessel disease and an involvement of proximal coronary tracts. They were commonly treated with PCI, with similar outcomes compared to those treated conservatively.
AB - Background/Objectives: To date, data regarding the characteristics and management of obstructive, stable coronary artery disease (CAD) encountered in patients undergoing transcatheter aortic valve implantation (TAVI) are sparse. The aim of the study was to analyze granular details, treatment, and outcomes of patients undergoing TAVI with obstructive, stable CAD from real-world practice. Methods: REVASC-TAVI (Management of myocardial REVASCularization in patients undergoing Transcatheter Aortic Valve Implantation with coronary artery disease) is an investigator-initiated, multicenter registry, which collected data from patients undergoing TAVI with obstructive stable CAD found during the pre-TAVI work-up. Results: A total of 2025 patients from 30 centers worldwide with complete follow-up were included in the registry. Most patients had single-vessel CAD (56.1%). An involvement of proximal coronary tracts was detected in 62.5% of cases, with 12.0% of patients having CAD in left main (LM). Most patients received percutaneous coronary intervention (PCI) (n = 1617, 79.9%), especially those with proximal CAD (90.4%). At 2 years, the rates of all-cause death [Kaplan-Meier (KM) estimates 20.1% vs. 18.8%, plog-rank = 0.86] and of the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure (KM estimates 29.7% vs. 27.5%, plog-rank = 0.82) did not differ between patients undergoing PCI and those who were not. Conclusions: Patients undergoing TAVI with obstructive CAD more commonly had a single-vessel disease and an involvement of proximal coronary tracts. They were commonly treated with PCI, with similar outcomes compared to those treated conservatively.
KW - coronary artery disease
KW - percutaneous coronary intervention
KW - transcatheter aortic valve implantation
KW - coronary artery disease
KW - percutaneous coronary intervention
KW - transcatheter aortic valve implantation
UR - https://publicatt.unicatt.it/handle/10807/283477
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85197172666&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85197172666&origin=inward
U2 - 10.3390/jcm13123497
DO - 10.3390/jcm13123497
M3 - Article
SN - 2077-0383
VL - 13
SP - N/A-N/A
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 12
ER -